AstraZeneca Past Earnings Performance

Past criteria checks 1/6

AstraZeneca has been growing earnings at an average annual rate of 29.2%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 16.2% per year. AstraZeneca's return on equity is 15.9%, and it has net margins of 12.7%.

Key information

29.2%

Earnings growth rate

24.4%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	16.2%
Return on equity	15.9%
Net Margin	12.7%
Next Earnings Update	06 Feb 2025

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How AstraZeneca makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:AZN Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	51,206	6,495	18,081	11,477
30 Jun 24	49,133	6,440	18,268	10,955
31 Mar 24	47,611	6,331	18,365	10,662
31 Dec 23	45,811	5,955	18,025	10,299
30 Sep 23	44,994	5,896	18,258	9,922
30 Jun 23	44,485	6,163	17,732	9,782
31 Mar 23	43,840	4,705	17,425	9,642
31 Dec 22	44,351	3,288	17,422	9,529
30 Sep 22	45,155	2,040	17,425	9,134
30 Jun 22	44,038	-1,253	17,232	9,184
31 Mar 22	41,487	-1,063	15,623	8,535
31 Dec 21	37,417	112	14,673	8,049
30 Sep 21	32,816	1,471	13,651	7,831
30 Jun 21	29,528	3,771	12,270	6,888
31 Mar 21	27,583	3,977	11,808	6,448
31 Dec 20	26,617	3,196	11,586	5,901
30 Sep 20	25,871	2,497	10,909	5,653
30 Jun 20	25,699	2,148	11,367	5,504
31 Mar 20	25,247	1,522	11,652	5,471
31 Dec 19	24,384	1,335	11,438	5,349
30 Sep 19	24,137	2,056	12,134	5,442
30 Jun 19	23,071	2,188	11,317	5,338
31 Mar 19	22,403	2,408	10,880	5,313
31 Dec 18	22,090	2,155	10,822	5,299
30 Sep 18	21,450	2,422	9,850	5,251
30 Jun 18	22,342	2,677	9,885	5,378
31 Mar 18	22,238	2,804	9,625	5,358
31 Dec 17	22,465	3,001	9,406	5,455
30 Sep 17	22,273	3,542	9,251	5,507
30 Jun 17	21,740	3,870	9,049	5,501
31 Mar 17	22,292	3,390	9,645	5,586
31 Dec 16	23,002	3,499	9,743	5,679
30 Sep 16	23,816	2,465	10,464	5,790
30 Jun 16	24,062	2,221	10,784	5,800
31 Mar 16	24,766	2,921	10,796	5,808
31 Dec 15	24,708	2,825	11,024	5,660
30 Sep 15	25,025	1,696	11,796	5,392
30 Jun 15	25,689	1,180	12,255	5,361
31 Mar 15	26,144	1,279	12,280	5,180
31 Dec 14	26,547	1,233	12,219	5,001
30 Sep 14	26,675	1,030	11,601	4,975
30 Jun 14	26,316	2,022	10,977	4,438
31 Mar 14	25,786	2,049	10,476	4,428
31 Dec 13	25,806	2,556	10,057	4,281

Quality Earnings: AZN has a large one-off loss of $4.5B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: AZN's current net profit margins (12.7%) are lower than last year (13.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: AZN's earnings have grown significantly by 29.2% per year over the past 5 years.

Accelerating Growth: AZN's earnings growth over the past year (10.2%) is below its 5-year average (29.2% per year).

Earnings vs Industry: AZN earnings growth over the past year (10.2%) did not outperform the Pharmaceuticals industry 54.6%.

AstraZeneca Past Earnings Performance

Past criteria checks 1/6

Key information

Recent past performance updates

Recent updates

AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity

AstraZeneca PLC Revises Earnings Guidance for the Fiscal Year 2024

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca plc Announces Astrazeneca and Ionis' Wainzua (Eplontersen) Recommendation for Approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

AstraZeneca PLC Announces AIRSUPRA (Albuterol/Budesonide) Demonstrated Statistically Significant and Clinically Meaningful Reduction in the Risk of Severe Exacerbations in Patients with Intermittent or Mild Persistent Asthma in BATURA Phase III Trial

Astrazeneca’S CALQUENCE® (acalabrutinib) Receives Priority Review in the US for Patients with Untreated Mantle Cell Lymphoma

Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Cas Datifan in Combination with Volrustomig in Renal Cell Carcinoma

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Astrazeneca PLC Tagrisso Receives US Approval in Unresectable Stage III EGFR-Mutated Lung Cancer Lung Cancer

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

AstraZeneca: Buy This Big Pharma Stock At A Discount Now

AstraZeneca PLC’s FluMist Receives Approval for Self-Administration in the US

AstraZeneca PLC's Fasenra Approves in the US for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca Announces Positive Results from the Niagara Phase III Trial

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases

AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data

Astrazeneca Presents Interim Results from the Randomized NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Present At the WCLC 2024

Astrazeneca's Imfinzi Receives Approval in US for the Treatment of Resectable Non-Small Cell Lung Cancer Before and After Surgery

Astrazeneca's Supplemental Biologics License Application for Imfinzi (Durvalumab) Granted Priority Review and Breakthrough Therapy Designation for Patients with Limited-Stage Small Cell Lung Cancer in the US

Astrazeneca Announces Positive High-Level Results from an Interim Analysis of the Amplify Phase III Trial

FDA Advisory Committee Reviewes Astrazeneca's Imfinzi for Treatment of Resectable Non-Small Cell Lung Cancer Based on Aegean Phase III Trial Results

Astrazeneca plc Announces Voydeya Approved in Canada as Add-On Therapy to Ravulizumab or Eculizumab for Adults with the Rare Disease PNH Who Have Residual Hemolytic Anemia Due to Extravascular Hemolysis

Revenue & Expenses Breakdown

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies